Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

2.180 -0.020 (-0.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 444,799
Open 2.210
Bid (Size) 2.160 (1)
Ask (Size) 2.230 (150)
Prev. Close 2.200
Today's Range 2.160 - 2.250
52wk Range 2.000 - 5.200
Shares Outstanding 105,482,558
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire

Performance

YTD
-47.5%
-47.5%
1 Month
-8.4%
-8.4%
3 Month
-20.1%
-20.1%
6 Month
-47.0%
-47.0%
1 Year
-43.1%
-43.1%

More News

Read More
Earnings Scheduled For May 7, 2025
Via Benzinga
A Look at MaxCyte's Upcoming Earnings Report
Via Benzinga
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
From MaxCyte, Inc
Via GlobeNewswire
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
These stocks are moving in today's after hours session
Via Chartmill
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Earnings Scheduled For March 11, 2025
Via Benzinga
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
From MaxCyte, Inc
Via GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
From Glancy Prongay & Murray LLP
Via Business Wire
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
From MaxCyte, Inc
Via GlobeNewswire
MarketBeat Week in Review – 01/20 - 01/24
Via MarketBeat
Topics Economy Government World Trade
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
Via MarketBeat
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Announces Retirement of Board Member Art Mandell
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
From MaxCyte, Inc
Via GlobeNewswire

Frequently Asked Questions

Is MaxCyte, Inc. - Common Stock publicly traded?
Yes, MaxCyte, Inc. - Common Stock is publicly traded.
What exchange does MaxCyte, Inc. - Common Stock trade on?
MaxCyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MaxCyte, Inc. - Common Stock?
The ticker symbol for MaxCyte, Inc. - Common Stock is MXCT on the Nasdaq Stock Market
What is the current price of MaxCyte, Inc. - Common Stock?
The current price of MaxCyte, Inc. - Common Stock is 2.180
When was MaxCyte, Inc. - Common Stock last traded?
The last trade of MaxCyte, Inc. - Common Stock was at 06/30/25 04:00 PM ET
What is the market capitalization of MaxCyte, Inc. - Common Stock?
The market capitalization of MaxCyte, Inc. - Common Stock is 229.95M
How many shares of MaxCyte, Inc. - Common Stock are outstanding?
MaxCyte, Inc. - Common Stock has 230M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.